Celiac Disease Clinical Trial
Official title:
Prevention of Celiac Disease in Children at Genetic Risk - Optimized Introduction of Gluten and Follow-up of Immunization
Celiac disease is an autoimmune disease induced by wheat gluten. Destruction of epithelial
cells and microvilli on gut mucosa is causing a "flat mucosa" and an absorption defect. The
diagnosis is based on typical microscopical finding in biopsy specimens but serum antibodies
to tissue transglutaminase and certain gliadin peptides are strongly associated with the
pathology. Severe diarrhoea associated with growth disturbance in infancy was historically
characterising the disease but is nowadays rare. Clinically more mild forms including silent
disease are very common. Studies based on antibody screening and biopsies done in
autoantibody positive subjects have confirmed a frequency of about 1-2% in adult population.
Undiagnosed disease is associated with deficiencies of nutrients and vitamins leading to
various chronic symptoms like anaemia, osteoporosis and general fatigue. It has also been
recently found that undiagnosed celiac disease may be associated with general
underachievement in society probably associated with common psychological symptoms like
fatigue and depression during the adolescence. The disease is treated by complete
elimination of wheat, rye and barley in the diet, which is laborious and causing
considerable extra costs in nutrition.
Much progress has been recently made in understanding of the genetic background and immune
markers associated with the disease as well as in understanding those patterns of gluten
introduction in infancy, which might be connected to a high disease risk. Our aim in this
study is in the first phase to identify children at high genetic risk (around 10%) and in a
follow-up study to define:
1. Are the age, dose of gluten and presence of simultaneous breast feeding at the
introduction of gluten associated with the risk of celiac disease?
2. Is it possible to decrease the frequency of celiac disease by nutritional counselling?
3. Is it possible to predict development of celiac disease by immunological tests before
the development of mucosal lesion
If we can confirm, that optimising the conditions at the introduction of wheat gluten in
infancy diet significantly reduces the disease incidence, will this have an important effect
on the nutritional recommendations concerning the diet in infancy. Combining genetic
screening and immunological tests might also offer a way to reduce the frequency of celiac
disease and help in early diagnosis and organisation of an adequate treatment
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04349904 -
Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
|
||
Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
Completed |
NCT05810441 -
Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
|
||
Recruiting |
NCT05555446 -
Bovine Colostrum to Prevent Absorption of Gluten
|
Early Phase 1 | |
Completed |
NCT02754609 -
Hookworm Therapy for Coeliac Disease
|
Phase 1 | |
Terminated |
NCT01902368 -
Celiac Disease Screening
|
N/A | |
Completed |
NCT02472704 -
Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo
|
N/A | |
Completed |
NCT02312349 -
Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
|
||
Completed |
NCT01172665 -
Celiac Disease Database
|
||
Completed |
NCT01100099 -
HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00639444 -
Risk of Celiac Disease and Age at Gluten Introduction
|
N/A | |
Active, not recruiting |
NCT05425446 -
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
|
Phase 1 | |
Enrolling by invitation |
NCT02202681 -
Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule
|
N/A | |
Completed |
NCT00362856 -
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
|
Phase 2 | |
Terminated |
NCT03866538 -
Budesonide in Patients With Immune Mediated Enteropathies
|
Phase 4 | |
Recruiting |
NCT05135923 -
Glutenfree, Gut Microbiota and Metabolic Regulation
|
N/A | |
Completed |
NCT05052164 -
Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women
|
N/A | |
Completed |
NCT03775499 -
Probiotic BL NCC 2705 and Gluten Sensitivity
|
N/A | |
Completed |
NCT03707730 -
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
|
Phase 2 |